Eyecyte-RPE(Eyecyte-RPE) - 在研适应症：干性年龄相关性黄斑病变，地图样萎缩，黄斑变性_专利_临床

概要

基本信息

药物类型

细胞疗法

别名-

靶点-

作用机制-

治疗领域

遗传病与畸形眼部疾病

在研适应症

干性年龄相关性黄斑病变地图样萎缩黄斑变性

非在研适应症-

原研机构

Eyestem Research Pvt Ltd.初创企业

在研机构

Eyestem Research Pvt Ltd.初创企业

Oregon Health & Science University

非在研机构-

最高研发阶段临床1/2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

2

项与 Eyecyte-RPE 相关的临床试验

NCT06394232 / Recruiting临床1/2期

A Phase 1/2a Multi-Center, Dose-Escalation Study to Evaluate the Safety & Efficacy of Eyecyte-RPE™ When Administered as a Single-dose Subretinal Injection in Subjects With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration

The goal of this clinical study is to evaluate the safety and efficacy of novel stem cell formulation in patients having Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (d-AMD).
The main questions it aims to answer are:
* Safety and tolerability of the novel stem cell formulation
* Potential efficacy of the novel stem cell formulation
Participants will receive a single subretinal injection in their study eye and followed up for safety.
This is an India only study and the product is developed indigenously.

开始日期2024-06-04

申办/合作机构

Eyestem Research Pvt Ltd.初创企业

CTRI/2024/04/065639 / Not yet recruiting临床1/2期

A Phase 1/2a Multi-Center Dose-Escalation Dose-Expansion Study toEvaluate the Safety and Efficacy of Eyecyte-RPE™ when administered as aSingle-dose Subretinal Injection in Subjects with Geographic AtrophyGA Secondary to Dry Age-related Macular Degeneration d-AMD - NIL

开始日期2024-05-13

申办/合作机构

Eyestem Research Pvt Ltd.初创企业

100 项与 Eyecyte-RPE 相关的临床结果

登录后查看更多信息

100 项与 Eyecyte-RPE 相关的转化医学

登录后查看更多信息

100 项与 Eyecyte-RPE 相关的专利（医药）

登录后查看更多信息

100 项与 Eyecyte-RPE 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
干性年龄相关性黄斑病变	临床2期	印度	Eyestem Research Pvt Ltd.初创企业	2024-06-04
地图样萎缩	临床2期	印度	Eyestem Research Pvt Ltd.初创企业	2024-06-04
黄斑变性	临床前	印度	Oregon Health & Science University	-
黄斑变性	临床前	美国	Oregon Health & Science University	-